

## Special Issue

# Pharmacological Mechanisms and Target Discovery in Lung Injury-Driven Fibrosis: From Molecular Pathways to Preclinical Innovation

### Message from the Guest Editor

This Special Issue will delve into the molecular and pharmacological underpinnings of lung injury and fibrosis, focusing on non-clinical advancements. Potential topics include the following:

- Mechanistic Drivers: Signaling cascades (TGF- $\beta$ , Wnt/ $\beta$ -catenin, DAMPs) connecting injury to fibroblast activation and extracellular matrix remodeling.
- Target Identification: AI- and multi-omics-guided discovery of novel targets (e.g., IL-11, epigenetic regulators, senescence-associated secretome).
- Drug Design: The structure-based optimization of small-molecule inhibitors, inhaled nanoparticle delivery systems, and senolytic agents.
- Preclinical Models: Advanced in vitro (e.g., 3D organoids) and in vivo systems to dissect injury–fibrosis interplay.

We invite the submission of reviews, original research, and methodological papers on molecular pharmacology, computational drug discovery, and experimental therapeutics.

### Guest Editor

Dr. Huifang Tang

Department of Pharmacology, School of Basic Medical Sciences, Zhejiang University, Hangzhou 310058, China

### Deadline for manuscript submissions

31 January 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/243386](https://mdpi.com/si/243386)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).